AstraZeneca and Insitro Form Cardiometabolic AI Alliance

Company AstraZeneca; Insitro Event Type Strategic Discovery and Licensing Collaboration Modality AI/ML-enabled target discovery (Virtual Human platform); modality-agnostic therapeutics Asset Selected discovery programs (undisclosed) Target Undisclosed causal targets Disease Area Metabolic dysfunction-associated steatohepatitis (MASH); cardiomyopathies Summary AstraZeneca entered a strategic discovery and licensing collaboration with…